Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial. Spravato ...

Compared with continuing dual antiplatelet therapy (DAPT) for 12 months after PCI, de-escalation to ticagrelor monotherapy reduces the risk of bleeding without increasing the risk of ischemic events, ...

Long-term maintenance with P2Y12 inhibitor monotherapy after discontinuing dual antiplatelet therapy (DAPT) in patients who’ve undergone PCI seems to reduce MACCE compared with aspirin monotherapy ...

Please provide your email address to receive an email when new articles are posted on . Dolutegravir monotherapy was safe and noninferior vs. combination ART. Switching to monotherapy from combination ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two ...

Just two months after the FDA lifted a clinical hold on trials of Innate Pharma’s lymphoma drug, the biotech has now dropped plans to pursue the anti-KIR3DL2 antibody as a monotherapy for a specific ...

Many patients with chronic lymphocytic leukemia (CLL) are treated with two- or three-drug regimens, but for some patients just one drug may be enough. Particularly for older patients or those who are ...

The update removes the requirement for Leqvio to be used as an adjunct to statin therapy. The Food and Drug Administration (FDA) has approved a labeling update for Leqvio ® (inclisiran) allowing for ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...